Targanta Therapeutics' mission is to build a better antibiotic. The biopharmaceutical company is developing new treatments for severe, drug-resistant bacterial infections, including those that attack the skin, blood, and bone. Its lead candidate is oritavancin, which may treat both skin and blood infections; the drug was first discovered by Eli Lilly and further developed by InterMune, from whom Targanta acquired the rights in 2005. The company plans to develop other antibiotics in addition to oritavancin; it is working on one earlier-stage candidate that may fight osteomyelitis, an inflammation of the bone caused by infection.
Targanta Therapeutics Corporation is a biopharmaceutical company focused on the development and commercialization of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company is developing its lead antibiotic, oritavancin, for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Targanta expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2008 seeking to commercialize oritavancin for the treatment of cSSSI. Additionally, Targanta is developing a number of antibacterial agents currently in pre-clinical development.
Targanta's strategy is to develop oritavancin into a leading therapy worldwide for the treatment of serious gram-positive infections, initially for the treatment of cSSSI and subsequently for other indications. Specifically, Targanta intends to:
* Obtain regulatory approval for oritavancin for the treatment of cSSSI in the U.S.;
* Build a hospital-directed sales force to commercialize oritavancin in the U.S.;
* Pursue clinical development of oritavancin in other dosing regimens and for additional indications;
* Submit a marketing authorization application (MAA) for oritavancin in the European Union and evaluate the potential for a blended commercialization strategy;
* Out-license oritavancin to third parties for development and commercialization in key Asian countries; and
* Pursue the development of other innovative antibiotics for the hospital market, either through in-licensing or internal development.